Why Essential Medicine Supply Chains Matter Now
National essential medicines suffer from low demand and low reimbursement prices, which makes them commercially unattractive — yet when supply stops, there is no substitute. With roughly 100 supply-disruption reports filed each year, the government is shifting toward a dual approach: expanding direct public importation while simultaneously pursuing public contract manufacturing.
The centerpiece is a standing public production and distribution network involving the government, medical associations, and the pharmaceutical industry. Instead of scrambling to find a manufacturer after a shortage occurs, the new structure shortens the lead time to production start and secures capacity in advance. For SME pharmaceutical companies, those two policy goals — faster start-up and larger production volume — translate directly into predictable demand.
Where the Opportunity Opens for SME Pharma
Many of the products targeted for public contract manufacturing are ones that large pharmaceutical companies discontinued or scaled back for margin reasons. A product requiring only tens of thousands of vials a year simply does not fit the batch economics of a large line — running it produces a loss. SME manufacturers operating small-volume, high-mix lines can flex batch sizes and therefore hold a structural advantage.
The self-sufficiency support program goes beyond simple contract manufacturing: it bundles process development funding with technical consulting. Because the government absorbs a meaningful share of process establishment costs, products that were previously unreachable on internal capital alone become viable candidates.
Participation Requirements
Profitability: Is There Actually Margin in Public Volume?
Judged on reimbursement price alone, many of these products look unprofitable. But three factors belong in the calculation. First, process development and equipment subsidies offset initial capital outlay. Second, public volume has low demand volatility, stabilizing utilization and creating a base for fixed-cost recovery. Third, the GMP track record and process data you accumulate become references for winning private CMO business later.
In practice, a workable allocation scenario is to treat public volume as a base load covering a set share of line utilization (say 30–40%) and fill the remainder with higher-margin private CMO orders.
A Practical Roadmap for Application Preparation
How KITIM Can Help
KITIM supports essential-medicine product selection and business feasibility review, self-sufficiency program proposal writing and process development project planning, and GMP line conformity diagnostics with validation advisory for capacity expansion. If you want to start by finding out which products are realistic for the lines you already operate, contact the KITIM consulting team.